What can rheumatologists learn from translational cancer therapy? by Sherlock JP et al.
 Newcastle University ePrints 
 
Sherlock JP, Filer AD, Isaacs JD, Buckley CD.  
What can rheumatologists learn from translational cancer therapy?  
Arthritis Research & Therapy 2013, 15: 114. 
 
Copyright: 
Authors of Research articles, Commentaries, Editorials, Letters, Meeting reports and Reviews articles 
published in Arthritis Research & Therapy are the copyright holders of their articles and have granted to 
any third party, in advance and in perpetuity, the right to use, reproduce or disseminate the article, 
according to the BioMed Central copyright and license agreement. 
Link to published article: 
http://dx.doi.org/10.1186/ar4203 
 
Date deposited: 2nd December 2014 
 
 
 
 
This work is licensed under a Creative Commons Attribution 4.0 International License 
 
 ePrints – Newcastle University ePrints 
http://eprint.ncl.ac.uk 
 
An intimate connection between infl ammation and 
cancer has been proposed for decades based upon both 
biological similarities and clinical observation. Numerous 
autoimmune diseases are associated with neoplasia, with 
an elevated risk of lymphoma in Sjögren’s syndrome [1] 
and rheumatoid arthritis [2], and gastrointestinal infl am-
mation in Crohn’s disease and ulcerative colitis is likewise 
associated with increased risk of intestinal neoplasia [3]. 
Infl ammation induced by infectious organisms may also 
result in neoplasia, as exemplifi ed by the association of 
Helicobacter pylori infection and gastric cancer, hepatitis 
C virus and hepatic cancer [4] and schistosomiasis and 
bladder cancer [5]. It has been estimated that 15% of 
malignancies may be caused by an underlying infection 
[6].
One of the most fundamental biological similarities 
between infl ammation and cancer is the presence of 
similar infl ammatory cells in these processes, and on 
occasions these immune cells have been demonstrated to 
be essential for tumour progression. Mast cells, for 
example, are required for tumour growth in a model of 
pancreatic cancer [7] and macrophages promote invasive, 
metastatic behaviour in murine mammary cancer [8]. 
Th e importance of these cellular similarities is under-
scored by the observation that inhibition of tyrosine 
kinase activity with imatinib is an established therapeutic 
strategy in systemic mastocytosis [9] and chronic myeloid 
leukaemia [10], but has also been reported to be eff ective 
in rheumatoid arthritis [11-13]. Tumours frequently 
manipulate the host immune response - for example, by 
secreting chemokines to induce a tolerogenic cellular 
microenvironment  - and may stimulate angiogenesis 
through elaboration of infl ammatory cytokines [14]. As 
well as cells, infl ammatory signalling molecules such as 
NF-kB are often shared between neoplastic and infl am-
matory conditions, and these molecules promote both 
processes. Th us, inactivation of this pathway in intestinal 
epithelial cells results in a direct reduction of tumour 
incidence, whereas its inactivation in myeloid cells, which 
cause infl ammation, results in a reduction of pro-
infl ammatory cytokines and resultant decrease in tumour 
size [15]. Similarly, both NF-κB and STAT-3 signalling 
pathways have been strongly implicated in hepatoma 
development [16]. Further examples of the shared role of 
molecules in neoplasia and infl ammatory arthritis 
include the Myc oncoprotein, which has also been shown 
to induce angiogenesis through the elaboration of IL-1β 
[17]. As well as this role in tumour vascularisation, this 
cytokine contributes to infl ammation in rheumatoid 
arthritis, as indicated by the eff ects of IL-1β neutralisation 
in this disease [18]. Given the importance of the signal-
ling pathway that operates through the mammalian target 
of rapamycin (mTOR) in both immune and neoplastic 
cells, attention is currently focussed on therapeutic 
approaches centred on this molecule for both auto-
immune and neoplastic pathologies [19,20].
Suggestions of a causal role of infl ammation in cancer 
emerge from the observation that the development of 
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neoplasia in response to infl ammation is strongly asso-
ciated with the chronicity and intensity of the infl am-
matory stimulus. Patients with high disease activity in 
rheumatoid arthritis thus have the highest chance of 
developing lymphoma [2]. Indeed, pro-infl ammatory 
molecules produced within infl ammatory lesions can 
themselves directly promote genomic instability, as 
exemplifi ed by reactive oxygen and nitrogen species that 
result in DNA damage [21]. Early experiments demon-
strated that culture with neutrophils elaborating reactive 
oxygen species endows fi broblasts with an ability to 
induce tumour development when transferred into mice 
[22]. Moreover, the rapid cell proliferation asso ciated 
with infl ammation results in further cellular susceptibility 
to DNA damage in an environment where, in addition, 
DNA repair processes are themselves com promised. Co-
culture of activated neutrophils with human alveolar 
epithelial cells reveals that neutrophils and the hypo-
chlorous acid that they produce can strongly inhibit 
nucleotide excision repair (NER) of damaged DNA and 
this eff ect can be abrogated by inhibiting production of 
hypochlorous acid [23]. Infl ammatory cells, moreover, 
express tissue degradative enzymes and promote angio-
genesis, processes that aid neoplastic cells to metastasise.
Th at infl ammation itself can induce genetic mutation 
and thus predispose to neoplastic development is 
demonstrated by the spontaneous infl ammatory bowel 
disease that develops in interleukin-10 defi cient mice, 
since this is associated with a colonic mutation rate fi ve 
times greater than wild-type mice, with a ten-fold 
increase in small deletions and insertions to DNA [24]. 
Indeed, mutations of p53 are found in both human 
infl ammatory bowel disease [25] and rheumatoid 
synovium [26]. In addition to compromised p53 activity 
through mutation, this molecule can also be functionally 
inhibited by the pro-infl ammatory molecule macrophage 
migration inhibitory factor [27], demonstrating another 
important means by which infl ammation, if unchecked, 
can potentially induce dysregulated cellular proliferation.
Th e shared use of chemokine receptors in driving both 
tissue-specifi c infl ammation and tissue-specifi c meta-
stases of neoplastic cells has received increasing atten-
tion. Indeed, the chemokine receptors CXCR4 and CCR7 
are expressed on breast cancer tumours and metastases, 
and their ligands highly expressed in the preferential 
metastatic sites [28]. Diff erential expression of chemokine 
receptors on diff erent tumours and their ligands in 
metastatic sites explains the diff erential patterns of 
metastases, just as these molecules co-ordinate immune 
cell traffi  cking.
Th e extremely potent pro-infl ammatory cytokine IL-23 
demonstrates a further central connection between 
autoimmune disease and cancer. Th is cytokine is central 
to autoimmune infl ammation and has been shown to 
play a fundamental role in spondyloarthropathy, for 
which it is a promising therapeutic target [29]. However, 
IL-23 is also expressed within the vast majority of human 
carcinomas, where it promotes infl ammation and 
expression of degradative enzymes such as MMP9 [30]. 
In neoplastic settings, IL-23 inhibits protective anti-
tumour immunity. In addition to IL-23, other pro-
infl ammatory cytokines have been demonstrated to be 
important in promoting neoplasia, with TNF, IL-1 and 
IL-6 playing key roles in ovarian cancer [31], and these 
molecules are established therapeutic targets that are 
neutralised in routine clinical practice for rheumatoid 
arthritis [18,32,33].
Th e intimate connection between infl ammation and 
cancer has encouraged the use of anti-infl ammatory 
agents to halt neoplastic development. Indeed, aspirin 
has been shown to reduce the incidence of cancer [34] 
and mice with defi ciency in the COX enzymes that this 
drug targets have reduced skin tumorigenesis [35]. 
Indeed, the reduced incidence of gastrointestinal and 
gynaecological cancers in rheumatoid arthritis patients 
has been attributed to non-steroidal anti-infl ammatory 
drug (NSAID) use [36]. Many chemotherapeutic agents 
are in clinical use not only for treatment of cancer, but 
also for immune-mediated infl ammation, prime examples 
being cyclophosphamide and methotrexate. Moreover, 
modern biological agents are also effi  cacious in both 
settings. Th us, rituximab is used to treat haematological 
malignancy, being eff ective in follicular and mantle cell 
lymphoma and diff use large B cell lymphoma [37], but 
also signifi cantly improves clinical outcomes in rheu ma-
toid arthritis [38]. Even TNF blockade, which some view 
as potentially facilitating oncogenesis, may also be viewed 
as protective against cancer development with recent 
studies conducted in renal cell and ovarian carcinoma 
[39-42].
Both infl ammatory conditions [43] and cancer [44] are 
associated with extensive modulation of local stromal 
tissue, with elaboration of pro-infl ammatory molecules. 
Moreover, the aforementioned mutations in p53 in 
rheumatoid synovium occur in islands of the intimal 
lining, most likely in type B fi broblast-like synoviocytes, 
and this is associated with elevated production of IL-6, 
the latter itself driving infl ammation. Indeed, infl am ma-
tion itself is worse in mice defi cient in p53, which develop 
more severe collagen-induced arthritis [45]. Given the 
success of agents targeting cancer-associated stromal 
cells in general and the fi broblast markers FAP [46] and 
CD248 [47] in particular, targeting similar pathogenic 
stromal cells in immune-mediated infl ammation has 
already shown [48], and is likely to continue to show, 
considerable promise.
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